This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Obayashi, P. A. C. Search for Related Content PubMed PubMed Citation Articles by Obayashi, P. A. C. Social Bookmarking                         What's this?

Posttransplant Diabetes Mellitus: Cause, Impact, and Treatment Options

Department of Clinical Nutrition, Stanford Hospital and Clinics, Stanford University Medical Center, Stanford, California

Correspondence: Correspondence: Patricia A. C. Obayashi, MS, RD, CDE, Clinical Dietitian, Department of Clinical Nutrition, Stanford Hospital and Clinics, Stanford University Medical Center, 300 Pasteur Drive, Room #H1207, M/C 5226 Stanford, CA 94305. Electronic mail may be sent to pobayashi{at}stanfordmed.org.

The incidence of diabetes mellitus (DM) is increased in adult organ transplant recipients. As many as 30% to 45% of solid organ adult transplant patients have DM before transplantation or develop posttransplant diabetes mellitus (PTDM). Risk factors for PTDM include family history, ethnic or genetic background, insulin resistance, and diabetogenic effects of immunosuppressive medications. Posttransplant hyperglycemia may result in increased platelet aggregation, increased wound infections, dehydration, and loss of lean body mass. More significantly, long-term complications of DM such as coronary artery disease and peripheral vascular disease may be exacerbated with the use of immunosuppressive medications whose known side effects include hyperglycemia, hyperlipidemia, and hypertension; these effects may lead to premature transplant graft dysfunction. Treatment goals for PTDM reflect those of the American Diabetes Association guidelines; long-term management is linked with early, patient-centered education and optimizing minimally diabetogenic immunosuppressive medication regimens. A multidisciplinary team including the patient, family/support people, transplant surgeon, transplant physician, transplant nurse coordinator, transplant social worker, pharmacist, dietitian, and diabetes educator is crucial to long-term management of PTDM.

Nutrition in Clinical Practice, Vol. 19, No. 2, 165-171 (2004)
DOI: 10.1177/0115426504019002165


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				W. Aasebo, K. Midtvedt, T. Gretland Valderhaug, T. Leivestad, A. Hartmann, A. Varberg Reisaeter, T. Jenssen, and H. Holdaas Impaired glucose homeostasis in renal transplant recipients receiving basiliximab Nephrol. Dial. Transplant., November 23, 2009; (2009) gfp617v1. [Abstract] [Full Text] [PDF]